Solid Bio safely doses DMD gene therapy after exiting FDA hold
Solid Biosciences has given its Duchenne muscular dystrophy (DMD) gene therapy without causing the sort of adverse events that forced it to shutter the study in 2019. The experience provides early evidence that the manufacturing changes and clinical mitigation strategy could rescue the program.